Month

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)

Investigation of the Neutralizing Antibody Response of Healthcare Workers at a Korean University Hospital Six Months After the Introduction of the COVID-19 Vaccine

Serologic Status and SARS-CoV-2 Infection over 6 Months of Follow Up in Healthcare Workers in Chicago: A Cohort Study

SARS-CoV-2 Genetic Diversity and Lineage Dynamics in Egypt during the First 18 Months of the Pandemic

Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021

프라이밍, 부스팅 및 하이브리드 면역에 따른 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 항체 매개 면역원성: 이스라엘 의료 종사자 집단의 11개월 추적 관찰에서 얻은 통찰력, 2020년 12월-2021년 10월

Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination

코로나바이러스 질병 2019 BNT162b2 mRNA 백신 접종 후 6개월 동안 의료 종사자 및 요양원 거주자 사이에서 백신 유도 항체 수준 및 중화 활성의 상당한 감소

Healthcare-Associated SARS-CoV-2 Reinfection after 3 Months with a Phylogenetically Distinct Omicron Variant: A Case Report